Video Programs

An expert discusses how addressing unmet needs in early diagnosis, treatment options, and long-term management, alongside exploring targeted therapies, combination approaches, and advancements in stem cell transplantation, holds promise for more effective and less toxic treatments for blastic plasmacytoid dendritic cell neoplasm (BPDCN).

An expert discusses how structuring clear roles, fostering communication, and using technology in the shared-care model between academic and community centers, alongside monitoring blood glucose levels, kidney function, and comorbidities, ensures effective collaboration and safe use of tagraxofusp (TAG) therapy.

An expert discusses how effective use of tagraxofusp in blastic plasmacytoid dendritic cell neoplasm (BPDCN) requires proactive monitoring for capillary leak syndrome, liver toxicity, and myelosuppression, with structured protocols and multidisciplinary coordination—especially in community settings—to ensure early intervention and safe, successful treatment delivery.

An expert discusses how treatment selection in blastic plasmacytoid dendritic cell neoplasm (BPDCN) involves balancing disease-specific targeting and patient fitness, with tagraxofusp remaining the frontline standard due to its efficacy and favorable hematologic recovery, whereas venetoclax/azacitidine may be reserved for less fit patients or relapsed settings.

An expert discusses how effective blastic plasmacytoid dendritic cell neoplasm (BPDCN) management requires early central nervous system (CNS) evaluation and a multidisciplinary approach, with treatment decisions guided by disease burden, patient fitness, and CNS involvement—highlighting the need for systemic tagraxofusp combined with prompt intrathecal therapy to address high-risk features.

Panelists discuss how Janus kinase (JAK) inhibitors like pacritinib offer crucial treatment options for myelofibrosis patients with severe thrombocytopenia (platelet counts <50,000 ), highlighting its advantages in providing significant spleen volume reduction (29% vs 3% in PERSIST-2 trial) while also offering unexpected anemia benefits possibly due to ACVR1 inhibition, with clinicians noting they set realistic expectations about platelet stabilization rather than improvement when counseling patients.

Panelists discuss how Janus kinase (JAK) inhibitor dosing strategies must be carefully tailored for anemic myelofibrosis patients, with clinical experience suggesting starting at lower doses (10 mg twice daily ) and gradually escalating based on the REALIZE trial approach, while balancing efficacy goals against cytopenia risks and monitoring unique toxicity profiles of different JAK inhibitors including Wernicke encephalopathy with fedratinib and gastrointestinal issues with pacritinib.

An expert discusses how the diagnosis and management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) require careful recognition of characteristic dermatologic and hematologic features, with tagraxofusp as frontline therapy and vigilant monitoring for central nervous system (CNS) involvement and treatment-related toxicities to guide a multidisciplinary care approach.

A panelist discusses how the MARIPOSA, SKIPPirr, and COCOON studies highlight the significant overall survival benefit of the amivantamab and lazertinib combination in first-line treatment for EGFR-mutant non–small cell lung cancer (NSCLC), while also emphasizing the importance of proactive management of adverse events (AEs), which may shift the standard of care and improve patient tolerability and adherence.

A panelist discusses how strategies such as clear patient education, simplified skin care regimens, personalized recommendations, and regular follow-ups, along with family involvement and addressing barriers to adherence, can significantly improve patient adherence to prophylactic dermatologic care, leading to better management of dermatologic adverse events (DAEs) in cancer treatment.

Panelists discuss how survival data from the COMFORT trials support the use of ruxolitinib in myelofibrosis, especially in intermediate- to high-risk patients with significant symptom burden or splenomegaly, while highlighting the need to consider patient selection, crossover effects, and real-world applicability when interpreting these results.

A panelist discusses how proactive management of dermatologic adverse events (DAEs) in cancer treatment, through early detection, tailored interventions, and collaboration with specialists such as dermatologic oncologists, advanced practice providers (APPs), and pharmacists, significantly enhances patient comfort, treatment adherence, and overall outcomes.

Panelists discuss how posttransplant cyclophosphamide has changed the clinical presentation of chronic graft-vs-host disease (cGVHD), with potentially lower incidence but similar severity when it does occur.

Panelists discuss how chronic graft-vs-host disease (cGVHD) results from complex biological mechanisms involving inflammation, loss of peripheral tolerance, and fibrotic pathways affecting multiple organ systems.

A panelist discusses how the treatment landscape for chronic graft-vs-host disease (cGVHD) has evolved significantly in recent years, with several pivotal clinical trials beyond REACH3 informing our approach, including the REACH1 and REACH2 trials for acute GVHD; the ROCKstar trial supporting belumosudil approval; and studies evaluating ibrutinib, axatilimab, and extracorporeal photopheresis.

Panelists discuss how clinical trial data from the COMFORT studies supports using Janus kinase (JAK) inhibitors such as ruxolitinib for myelofibrosis patients beyond the original high-risk study population, with experts noting they often treat intermediate-1-risk patients based on symptomatic burden and splenomegaly rather than risk stratification alone to achieve meaningful spleen volume reduction and symptom improvement.

Panelists discuss how treatment goals for intermediate-risk myelofibrosis patients focus on achieving meaningful clinical outcomes including relieving symptoms, preventing worsening of anemia, maintaining transfusion independence, reducing symptomatic splenomegaly, and ultimately improving survival while considering patient-specific factors like age and transplant eligibility.

A panelist discusses how the COCOON study's findings will lead to the integration of enhanced dermatologic management into clinical practice for patients receiving amivantamab and lazertinib, focusing on proactive care to reduce dermatologic adverse events (DAEs), improve patient comfort, and increase treatment adherence, ultimately optimizing patient outcomes.

Panelists discuss how initiating therapy in myelofibrosis requires a personalized approach that balances symptom burden, risk stratification, cytopenias, and patient goals, with treatment decisions—often involving Janus kinase (JAK) inhibitors—tailored to optimize both disease control and quality of life.

A panelist discusses how prophylactic dermatologic management, including the proactive use of moisturizers, topical steroids, and antibiotics, significantly improves the tolerability and adherence to first-line treatment with amivantamab and lazertinib for advanced non–small cell lung cancer (NSCLC) by reducing the severity of dermatologic adverse events (DAEs) and preventing treatment interruptions.

Panelists discuss how accurate risk stratification using clinical and molecular prognostic tools like DIPSS, MIPSS70, and GIPSS guides personalized treatment decisions in myelofibrosis, ranging from observation in low-risk patients to Janus kinase (JAK) inhibitor therapy and early transplant evaluation in higher-risk cases.

A panelist discusses how managing adverse events (AEs) in patients with chronic graft-vs-host disease (cGVHD) treated with ruxolitinib requires a structured monitoring approach that balances therapeutic efficacy with patient safety through regular clinical evaluations, laboratory assessments, and proactive management strategies tailored to individual risk profiles.

Panelists discuss how treatment selection among Janus kinase (JAK) inhibitors for myelofibrosis involves considering specific patient characteristics such as cytopenia profiles, mutation status, risk stratification using MIPS criteria, and balancing potential transplant candidacy with careful timing of JAK inhibitor therapy.

Panelists discuss how advancements in understanding myeloproliferative neoplasms are shaping treatment approaches through case studies of intermediate-risk myelofibrosis and advanced polycythemia vera, with emphasis on Janus kinase (JAK) inhibitor selection based on genetic profiles and patient-specific factors.

Panelists discuss how distinguishing pre-fibrotic myelofibrosis from other myeloproliferative neoplasms like essential thrombocythemia remains challenging due to overlapping clinical and molecular features, subjective histopathologic interpretation, and variable application of diagnostic criteria, underscoring the need for expert pathology review and multidisciplinary evaluation to guide accurate diagnosis and management.

Panelists discuss how evolving insights into myelofibrosis—driven by molecular profiling, risk-adaptive therapy, and emerging treatments—are reshaping clinical practice toward more personalized care, with increasing focus on managing cytopenias, treatment resistance, and long-term disease modification.

A panelist discusses how the COCOON study demonstrated that enhanced dermatologic management significantly reduces the incidence and severity of dermatologic adverse events (DAEs) in patients with locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) receiving first-line treatment with amivantamab and lazertinib, improving both quality of life and treatment adherence.

A panelist discusses how first-line (1L) therapies, including EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib, are the standard of care for treating locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC), with emerging combination strategies and safety considerations shaping current treatment approaches.